Reduces Symptoms
In an EAE model, treatment with relaxin reduced symptoms, demyelination and gliosis.
The Science
Relaxin
A first-in-class treatment for neurodegeneration
Promotes Remyelination
Relaxin treatment promotes differentiation and maturation of Oligodendrocytes and promotes remyelination in vivo.
Synergy with steroids
Relaxin has been shown to have synergistic effects with steroids; a first line therapy in concussion, TBI and MS.
Relaxin
Relaxin is a pleiotropic hormone
In cell culture and in vivo models relaxin reduced symptoms, decreased mRNA expression of pro-inflammatory cytokines and chemokine receptors, decreased lesion size and load, and decreased macrophage infiltration, preserved myelin and neurofilaments, reduced gliosis and promoted remyelination.
Relaxin - a new treatment for neurodegeneration
Targetting concussion/CTE, multipe sclerosis, motor neurone disease and Parkinson's disease.
BVBiomedical Ltd. is a research driven company developing novel therapeutic compounds for use in treating neuro-degenerative diseases.
Contacts
-
- Address
- Magdalen Centre, The Oxford Science Park, Robert Robinson Drive, Oxford, Oxfordshire OX4 4GA, U.K.
-
- Phone
-
- +44 751 879 5083
-
- info@bvbiomed.com